Helen Reeves

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease.

AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.

A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease.

The role of tobacco-derived carcinogens in pancreas cancer.

Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.

Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team.

The rate of production of uric acid by hepatocytes is a sensitive index of compromised cell ATP homeostasis.

The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.

Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area".

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.

Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.

Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases.

Hepatocellular carcinoma: optimal staging impacts survival.

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.

Assessment of the Hong Kong Liver Cancer Staging System in Europe.

Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?

Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.

Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.

Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

NAFLD-which patients should have hepatocellular carcinoma surveillance?

The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury.

Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Liquid biopsy for liver diseases.

Reply to 'Comment on 'Circulating Neutrophils in patients with hepatocellular carcinoma".

Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.

Weighing the benefits of hepatocellular carcinoma surveillance against potential harms.

The CCR2 Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

From NASH to HCC: current concepts and future challenges.

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma.

Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.

High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma.

Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials.

Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.

Neutrophils induce paracrine telomere dysfunction and senescence in ROS-dependent manner.

A Role in the Genetic Predisposition to NAFLD-HCC?

NAFLD-Associated HCC: Progress and Opportunities.

Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.

Combined hepatocellular-cholangiocarcinoma - More questions than answers.

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity.

Key features of the environment promoting liver cancer in the absence of cirrhosis.

Cell-free DNA TAPS provides multimodal information for early cancer detection.